NCT04828993 - The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

February 12, 2023

Study Completion Date

February 12, 2023

Conditions

Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Interventions

DRUG

tafamidis meglumine

Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).

Trial Locations (9)

Peking union hospital of Chinese academy of medical sciences, Beijing

Peking University First Hospital, Beijing

Xuanwu Hospital Capital Medical University, Beijing

Tiantan Hospital Capital Medical University, Beijing

Peking University Third Hospital, Beijing

Peking union hospital of Chinese academy of medical sciences, Beijing

Huashan Hospital Fudan University, Shanghai

The First Affiliated Hospital of Fujian Medical University, Fuzhou

NanFang Hospital of Southern Medical University, Guangzhou